Google
OBIO Stock Price & Analysis — Orchestra Biomed Holdings Inc. (Healthcare >> Biotechnology)
OBIO FAQ
What is OBIO's P/E ratio?
Orchestra Biomed Holdings Inc. (OBIO) currently trades at a P/E ratio of 39.50.
What is OBIO's ROE?
Orchestra Biomed Holdings Inc. reports a Return on Equity (ROE) of -107.20%.
What is OBIO's dividend yield?
Orchestra Biomed Holdings Inc. offers a dividend yield of 0.00%.
What is OBIO's Quality Score?
Our AI rates OBIO's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy OBIO?
Our AI Timing Score for OBIO is 64 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does OBIO belong to?
Orchestra Biomed Holdings Inc. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
OBIO AI Analysis Summary
Our AI summary for OBIO: Orchestra Biomed Holdings Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 39.50, ROE of -107.20%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 64/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 4.27
Price
-0.05
(-1.17%)
Day Change
|
|
|---|
OBIO, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.27 |
| PBV / Sector |
4.84 / 44,022.72
|
| Earning Per Share | -0.95 |
| PE / Sector |
39.50 / 19.17
|
| PEG or PE/Growth / Sector |
16.95 / 1.24
|
| Average 1M Daily Value |
0.73 M
GREAT
|
| Average 1W Daily Value |
0.64 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
64% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-05 08:00:37 |
| Symbol | OBIO |
| Name | ORCHESTRA BIOMED HOLDINGS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 59.88 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 246.71 / 9,586.08 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 150 Union Square Drive, New Hope, PA, United States, 18938
Phone: 215 862 5797
Website: https://www.orchestrabiomed.com
Employees: 86
Sector: Healthcare >> Biotechnology
Description: Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap